Loading stock data…
Apogee Therapeutics (APGE)
$132.65+0.10 (+0.08%)
Market OpenUpdated 9:52 AM EDT
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apogee Therapeutics, Inc. in the Healthcare sector is trading at $132.65 with a market capitalization of $6.4B. Wall Street consensus targets $130.53 (12 analysts), implying a -1.6% move over the next 12 months. The stock is currently near its 52-week high of $133.16, remaining 83.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$82.77M↓ | -$78.06M↓ | -$71.28M↑ | -$73.17M↓ | -$63.10M |
| Net Income | -$74.11M↓ | -$69.39M↓ | -$65.02M↑ | -$66.10M↓ | -$55.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indicat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.87%
Volume
Today's trading volume
210,998
Recent News
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on June 22, setting a $707 price target. However, the firm noted that AbbVie’s acquisition of Apogee Therapeutics, announced that morning, is a net negative for the company. […]
AbbVie (ABBV) Wins Health Canada Approval for Boey
AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, Allergan Aesthetics, an AbbVie Inc. (NYSE:ABBV) company, announced that Health Canada approved Boey for the temporary improvement of moderate to severe lines between the eyebrows in adults. Boey is the first and only approved botulinum […]
AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes […]
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
It has been a banner year for biotech buyouts, and these are two of the prime targets.
Is AbbVie a Buy After Its Purchase of Apogee?
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?